The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Aptamers in the Therapeutics and Diagnostics Pipelines
Open accessAbstract
Aptamers are short single-stranded DNA or RNA oligonucleotides that can selectively bind to small molecular ligands or protein targets with high affinity and specificity, by acquiring unique three-dimensional structures.Aptamers have the advantage of being highly specific, relatively small in size, non-immunogenic and can be easily stabilized by chemical modifications, thus allowing expansion of their diagnostic and therapeutic potential.Since the invention of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like macular degeneration, cancer, thrombosis and inflammatory diseases.Furthermore, owing to the aforementioned advantages and unique adaptability of aptamers to point-of-care platforms, aptamer technology has created a stable niche in the field of in vitro diagnostics by enhancing the speed and accuracy of diagnoses.The aim of this review is to give an overview on aptamers, highlight the inherent therapeutic and diagnostic opportunities and challenges associated with them and present various aptamers that have reached therapeutic clinical trials, diagnostic markets or that have immediate translational potential for therapeutics and diagnostics applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Aptamers evolved from live cells as effective molecular probes for cancer study
Shangguan, D., Li, Y., Tang, Z., Cao, Z. C., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. J., & Tan, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602615103 · Cited by 1,516
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Current approaches in SELEX: An update to aptamer selection technology
Darmostuk, M., Rimpelova, S., Gbelcova, H., & Ruml, T. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.008 · Cited by 702
RNA aptamers as reversible antagonists of coagulation factor IXa
Rusconi, C. P., Scardino, E., Layzer, J., Pitoc, G. A., Ortel, T. L., Monroe, D., & Sullenger, B. A. (2002) · Nature · doi:10.1038/nature00963 · Cited by 512
The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells
Soundararajan, S., Chen, W., Spicer, E. K., Courtenay-Luck, N., & Fernandes, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5723 · Cited by 512
Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., & Ruoslahti, E. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304132 · Cited by 497
Von Willebrand factor, platelets and endothelial cell interactions
Ruggeri, Z. M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00260.x · Cited by 486
Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes
Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., & Eckstein, F. (1991) · Science · doi:10.1126/science.1857967 · Cited by 463
Assessment of Variability in the SOMAscan Assay
Candia, J., Cheung, F., Kotliarov, Y., Fantoni, G., Sellers, B., Griesman, T., Huang, J., Stuccio, S., Zingone, A., Ryan, B. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14755-5 · Cited by 393
Small-Molecule Binding Aptamers: Selection Strategies, Characterization, and Applications
Ruscito, A., & DeRosa, M. C. (2016) · Frontiers in Chemistry · doi:10.3389/fchem.2016.00014 · Cited by 391
Inhibitory DNA Ligands to Platelet-Derived Growth Factor B-Chain
Green, L. S., Jellinek, D., Jenison, R., Östman, A., Heldin, C.-H., & Janjic, N. (1996) · Biochemistry · doi:10.1021/bi961544+ · Cited by 390
Point-of-Care Diagnostics in Low Resource Settings: Present Status and Future Role of Microfluidics
Sharma, S., Zapatero-Rodríguez, J., Estrela, P., & O'Kennedy, R. (2015) · Biosensors · doi:10.3390/bios5030577 · Cited by 349
Direct In Vitro Selection of a 2′-O-Methyl Aptamer to VEGF
Burmeister, P. E., Lewis, S. D., Silva, R. F., Preiss, J. R., Horwitz, L. R., Pendergrast, P. S., McCauley, T. G., Kurz, J. C., Epstein, D. M., Wilson, C., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.10.017 · Cited by 347
Aptamer-Controlled Reversible Inhibition of Gold Nanozyme Activity for Pesticide Sensing
Weerathunge, P., Ramanathan, R., Shukla, R., Sharma, T. K., & Bansal, V. (2014) · Analytical Chemistry · doi:10.1021/ac5028726 · Cited by 311
Self-citationKraemer, S., Vaught, J. D., Bock, C., Gold, L., Katilius, E., Keeney, T. R., Kim, N., Saccomano, N. A., Wilcox, S. K., Zichi, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026332 · Cited by 310
Pharmacokinetics and Biodistribution of Novel Aptamer Compositions
Healy, J. M., Lewis, S. D., Kurz, M., Boomer, R. M., Thompson, K. M., Wilson, C., & McCauley, T. G. (2004) · Pharmaceutical Research · doi:10.1007/s11095-004-7676-4 · Cited by 298
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
Hathout, Y., Brody, E., Clemens, P. R., Cripe, L., DeLisle, R. K., Furlong, P., Gordish-Dressman, H., Hache, L., Henricson, E., Hoffman, E. P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507719112 · Cited by 290
Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., BouFakhreddine, S., Holohan, T. V., & Schaub, R. G. (2007) · Circulation · doi:10.1161/circulationaha.107.724864 · Cited by 286
Ganson, N. J., Povsic, T. J., Sullenger, B. A., Alexander, J. H., Zelenkofske, S. L., Sailstad, J. M., Rusconi, C. P., & Hershfield, M. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.034 · Cited by 273
Hoellenriegel, J., Zboralski, D., Maasch, C., Rosin, N. Y., Wierda, W. G., Keating, M. J., Kruschinski, A., & Burger, J. A. (2014) · Blood · doi:10.1182/blood-2013-03-493924 · Cited by 242
Novel Approach to Specific Growth Factor Inhibition in Vivo
Floege, J., Ostendorf, T., Janssen, U., Burg, M., Radeke, H. H., Vargeese, C., Gill, S. C., Green, L. S., & Janjic, N. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65263-7 · Cited by 233
Aptamer-mediated ‘turn-off/turn-on’ nanozyme activity of gold nanoparticles for kanamycin detection
Sharma, T. K., Ramanathan, R., Weerathunge, P., Mohammadtaheri, M., Daima, H. K., Shukla, R., & Bansal, V. (2014) · Chem. Commun. · doi:10.1039/c4cc07275h · Cited by 231
Self-citationOligonucleotide aptamers that recognize small molecules
Famulok, M. (1999) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(99)80043-8 · Cited by 225
Selection and Biosensor Application of Aptamers for Small Molecules
Pfeiffer, F., & Mayer, G. (2016) · Frontiers in Chemistry · doi:10.3389/fchem.2016.00025 · Cited by 224
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223 · cited 4×
“Using this platform in a recent study, two novel myocardial injury markers, Dickkopf-related protein 4, a WNT pathway inhibitor, and cripto, a growth factor important in cardiac development, were identified [111].”
BackgroundMethodInfluentialDyke, C. K., Steinhubl, S. R., Kleiman, N. S., Cannon, R. O., Aberle, L. G., Lin, M., Myles, S. K., Melloni, C., Harrington, R. A., Alexander, J. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.668434 · Cited by 222
Aptamer Therapeutics in Cancer: Current and Future
Morita, Y., Leslie, M., Kameyama, H., Volk, D., & Tanaka, T. (2018) · Cancers · doi:10.3390/cancers10030080 · Cited by 217
An aptamer-based dipstick assay for the rapid and simple detection of aflatoxin B1
Shim, W.-B., Kim, M. J., Mun, H., & Kim, M.-G. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.06.059 · Cited by 214
Ostroff, R., Bigbee, W., Franklin, W., Gold, L., Mehan, M., Miller, Y., Pass, H., Rom, W., Siegfried, J., Stewart, A., et al. (2010) · Nature Precedings · doi:10.1038/npre.2010.4537.1 · Cited by 213
Wu, W., Zhao, S., Mao, Y., Fang, Z., Lu, X., & Zeng, L. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.12.041 · Cited by 212
Aptamer-based point-of-care diagnostic platforms
Dhiman, A., Kalra, P., Bansal, V., Bruno, J. G., & Sharma, T. K. (2017) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2017.02.060 · Cited by 206
Self-citationMenne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., Więcek, A., Haller, H., & for the Emapticap Study Group (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv459 · Cited by 201
Simple Methods and Rational Design for Enhancing Aptamer Sensitivity and Specificity
Kalra, P., Dhiman, A., Cho, W. C., Bruno, J. G., & Sharma, T. K. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00041 · Cited by 184
Self-citationPlasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years
Blann, A. (2006) · Thrombosis and Haemostasis · doi:10.1160/th05-07-0527 · Cited by 175
ABCs of DNA aptamer and related assay development
Sharma, T. K., Bruno, J. G., & Dhiman, A. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.01.003 · Cited by 174
Self-citationCurrent Advances in Aptamers for Cancer Diagnosis and Therapy
Hori, S.-I., Herrera, A., Rossi, J., & Zhou, J. (2018) · Cancers · doi:10.3390/cancers10010009 · Cited by 169
Aptamers: The “evolution” of SELEX
Wu, Y. X., & Kwon, Y. J. (2016) · Methods · doi:10.1016/j.ymeth.2016.04.020 · Cited by 164
Soh, J. H., Lin, Y., Rana, S., Ying, J. Y., & Stevens, M. M. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00875 · Cited by 162
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158
Duerschmied, D., Merhi, Y., Tanguay, J., Hutabarat, R. M., GILBERT, J., Wagner, D. D., Schaub, R. G., Diener, J. L., & Lagassé, H. A. D. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03459.x · Cited by 156
Derivation of RNA aptamer inhibitors of human complement C5
Biesecker, G., Dihel, L., Enney, K., & Bendele, R. A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00020-x · Cited by 152
SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy
Roccaro, A. M., Sacco, A., Purschke, W. G., Moschetta, M., Buchner, K., Maasch, C., Zboralski, D., Zöllner, S. K., Vonhoff, S., Mishima, Y., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.042 · Cited by 148
Semenkovich, C. F., Ostlund, R. E., Olson, M. O. J., & Yang, J. W. (1990) · Biochemistry · doi:10.1021/bi00493a028 · Cited by 146
Waters, E. K., Genga, R. M. J., Schwartz, M. C., Nelson, J. A., Schaub, R. G., Olson, K. A., Kurz, J. C., & McGinness, K. E. (2011) · Blood · doi:10.1182/blood-2010-10-311936 · Cited by 143
Probing High Affinity Sequences of DNA Aptamer against VEGF165
Kaur, H., & Yung, L. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031196 · Cited by 141
Self-citationTargeting monocyte chemoattractant protein-1 signalling in disease
Dawson, J., Miltz, W., Mir, A. K., & Wießner, C. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.1.35 · Cited by 133
Chan, M. Y., Cohen, M. G., Dyke, C. K., Myles, S. K., Aberle, L. G., Lin, M. J., Walder, J. S., Steinhubl, S. R., Gilchrist, I. C., Kleiman, N. S., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.745687 · Cited by 130
Evoking picomolar binding in RNA by a single phosphorodithioate linkage
Abeydeera, N., Egli, M., Cox, N., Mercier, K., Conde, J. N., Pallan, P. S., Mizurini, D. M., Sierant, M., Hibti, F.-E., Hassell, T., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw725 · Cited by 122
Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment
Groote, M. A. D., Nahid, P., Jarlsberg, L. G., Johnson, J. L., WEINER, M. H., Muzanyi, G., Janjić, N., Sterling, D. G., & Ochsner, U. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061002 · Cited by 115
Parashar, A. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/18712.7922 · Cited by 114
Beyond antibodies: New affinity reagents to unlock the proteome
Lollo, B. A., Steele, F. R., & Gold, L. (2014) · PROTEOMICS · doi:10.1002/pmic.201300187 · Cited by 110
Oberthüer, D., Achenbach, J., Gabdulkhakov, A. G., Buchner, K., Maasch, C., Falke, S., Rehders, D., Klußmann, S., & Betzel, C. (2015) · Nature Communications · doi:10.1038/ncomms7923 · Cited by 104
Choi, E. W., Nayak, L. V., & Bates, P. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1088 · Cited by 102
Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
Musumeci, D., Platella, C., Riccardi, C., Moccia, F., & Montesarchio, D. (2017) · Cancers · doi:10.3390/cancers9120174 · Cited by 97
Groote, M. A. D., Sterling, D. G., Hraha, T. H., Russell, T. M., Green, L. S., Wall, K. M., Kräemer, S., Ostroff, R. M., Janjić, N., & Ochsner, U. A. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00467-17 · Cited by 96
Protein Signature of Lung Cancer Tissues
Mehan, M. R., Ayers, D. G., Thirstrup, D. J., Xiong, W., Ostroff, R. M., Brody, E. N., Walker, J. J., Gold, L., Jarvis, T. C., Janjić, N., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035157 · Cited by 92
Toward third-generation aptamers: Spiegelmers and their therapeutic prospects.
Vater, A., & Klußmann, S. (2003) · PubMed · Cited by 91
CFP10 and ESAT6 aptamers as effective Mycobacterial antigen diagnostic reagents
Tang, X., Zhou, Y.-X., Wu, S., Pan, Q., Xia, B., & Zhang, X. (2014) · Journal of Infection · doi:10.1016/j.jinf.2014.05.015 · Cited by 85
Vater, A., Sahlmann, J., Kröger, N., Zöllner, S. K., Lioznov, M. V., Maasch, C., Buchner, K., Vossmeyer, D., Schwoebel, F., Purschke, W. G., et al. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.58 · Cited by 84
Boyce, M. J., Warrington, S., Cortezi, B., Zöllner, S. K., Vauléon, S., Swinkels, D. W., Summo, L., Schwoebel, F., & Riecke, K. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13433 · Cited by 83
Ludwig, H., Weisel, K. C., Petrucci, M. T., Leleu, X. P., Cafro, A. M., Garderet, L., Leitgeb, C., Foà, R., Greil, R., Yakoub‐Agha, I., et al. (2017) · Leukemia · doi:10.1038/leu.2017.5 · Cited by 80
Watson, S. R., Chang, Y.-F., O'Connell, D., WEIGAND, L., Ringquist, S., & Parma, D. H. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.63 · Cited by 79
Lavu, P. S. R., Mondal, B., Ramlal, S., Murali, H. S., & Batra, H. V. (2016) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00123 · Cited by 79
Selective Targeting and Inhibition of Yeast RNA Polymerase II by RNA Aptamers
Thomas, M., Chédin, S., Carles, C., Riva, M., Famulok, M., & Sentenac, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.27980 · Cited by 77
Yunn, N.-O., Koh, A., Han, S., Lim, J. H., Park, S., Lee, J., Kim, E., Jang, S. K., Berggren, P., & Ryu, S. H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv767 · Cited by 71
Kawa, M. P., Machalińska, A., Rogińska, D., & Machaliński, B. (2014) · Journal of Immunology Research · doi:10.1155/2014/483960 · Cited by 66
Darfeuille, F., Reigadas, S., Hansen, J. B., Ørum, H., Primo, C. D., & Toulmé, J. (2006) · Biochemistry · doi:10.1021/bi0606344 · Cited by 65
In Vitro antibacterial effects of antilipopolysaccharide DNA aptamer-C1qrs complexes
Bruno, J. G., Carrillo, M. P., & Phillips, T. (2008) · Folia Microbiologica · doi:10.1007/s12223-008-0046-6 · Cited by 63
Self-citationSix-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF
Ashley, S. L., Xia, M., Murray, S., O’Dwyer, D. N., Grant, E. P., White, E. S., Flaherty, K. R., Martínez, F. J., & Moore, B. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159878 · Cited by 62
Complement dysregulation in AMD: RPE-Bruch’s membrane-choroid
Sparrow, J. R., Ueda, K., & Zhou, J. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.03.007 · Cited by 60
Clarke, J. R., Marquardt, R. R., Oosterveld, A., Frohlich, A. A., Madrid, F. J., & Dawood, M. R. (1993) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf00034a050 · Cited by 60
Potential Capacity of Aptamers to Trigger Immune Activation in Human Blood
Avci‐Adali, M., Steinle, H., Michel, T., Schlensak, C., & Wendel, H. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068810 · Cited by 59
The selection and application of ssDNA aptamers against MPT64 protein in Mycobacterium tuberculosis
Qin, L., Zheng, R., Ma, Z.-Z., Feng, Y., Liu, Z., Yang, H., Wang, J., Jin, R., Lu, J., Ding, Y., et al. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.097 · Cited by 59
Therapeutic aptamers: developmental potential as anticancer drugs
Lee, J. W., Kim, H. J., & Heo, K. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.4.277 · Cited by 57
Gorczyca, M. E., Nair, S. C., Jilma, B., Priya, S., Male, C., Reitter, S. E., Knöbl, P., Gilbert, J. C., Schaub, R. G., Dockal, M., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04790.x · Cited by 57
Development of a Protein Biomarker Panel to Detect Non–Small-Cell Lung Cancer in Korea
Jung, Y. J., Katilius, E., Ostroff, R. M., Kim, Y., Seok, M., Lee, S., Jang, S., Kim, W. S., & Choi, C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.012 · Cited by 47
Mena, A., Nichani, A., Popowych, Y., Godson, D. L., Dent, D., Townsend, H. G. G., Mutwiri, G., Hecker, R., Babiuk, L. A., & Griebel, P. J. (2003) · Immunology · doi:10.1046/j.1365-2567.2003.01722.x · Cited by 44
Eid, C., Palko, J. W., Katilius, E., & Santiago, J. G. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00886 · Cited by 43
Investigating the Antiproliferative Activity of High Affinity DNA Aptamer on Cancer Cells
Kaur, H., Li, J. J., Bay, B., & Yung, L. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0050964 · Cited by 41
Self-citationCharacterization of Structure and Metal Ions Specificity of Co2+-Binding RNA Aptamers
Wrzesiński, J., & Ciesiołka, J. (2005) · Biochemistry · doi:10.1021/bi047397u · Cited by 36
Russell, T. M., Green, L. S., Rice, T., Kruh‐Garcia, N. A., Dobos, K. M., Groote, M. A. D., Hraha, T. H., Sterling, D. G., Janjić, N., & Ochsner, U. A. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00469-17 · Cited by 35
NOX-A12: mobilizing CLL away from home
Marasca, R., & Maffei, R. (2014) · Blood · doi:10.1182/blood-2013-12-542480 · Cited by 34
Sadiq, M. A., Hanout, M., Sarwar, S., Hassan, M., Diana, V., Nguyen, Q. D., & Sepah, Y. J. (2015) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2015.05.005 · Cited by 34
Sadiq, M. A., Hanout, M., Sarwar, S., Hassan, M., Agarwal, A. K., Sepah, Y. J., Diana, V., & Nguyen, Q. D. (2015) · Developments in ophthalmology · doi:10.1159/000438953 · Cited by 32
Tsai, S.-C., Hung, L.-Y., & Lee, G. (2017) · Biomicrofluidics · doi:10.1063/1.4991476 · Cited by 29
Aptamers as therapeutic middle molecules
Nakamura, Y. (2017) · Biochimie · doi:10.1016/j.biochi.2017.10.006 · Cited by 28
Thet, N. T., & Jenkins, A. T. A. (2015) · Electrochemistry Communications · doi:10.1016/j.elecom.2015.01.001 · Cited by 27
Laboratories, M., Bruno, J. G., Phillips, T., Montez, T., García, A., Sivils, J. C., Mayo, M. W., & Greis, A. P. (2014) · Journal of Fluorescence · doi:10.1007/s10895-014-1495-8 · Cited by 27
Self-citationChang, J., Chantrathammachart, P., Monroe, D. M., & Key, N. S. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.05.010 · Cited by 24
Factor IXa as a target for anticoagulation in thrombotic disorders and conditions.
Smiley, D. A., & Becker, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.028 · Cited by 18
Cited by
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
The Era of Digital Health: A Review of Portable and Wearable Affinity Biosensors
Tu, J., Torrente‐Rodríguez, R. M., Wang, M., & Gao, W. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906713 · Cited by 357
Therapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.118 · Cited by 288
The impact of protein corona on the biological behavior of targeting nanomedicines
Farshbaf, M., Valizadeh, H., Panahi, Y., Fatahi, Y., Chen, M., Zarebkohan, A., & Gao, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121458 · Cited by 95
Metadata
- Authors
- Kaur, H., Bruno, J. G., Kumar, A., & Sharma, T. K.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 15
- Pages
- 4016-4032
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2884141826
- Cited by
- 366
- References
- 97
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.